Nonhormonal options for menopause symptoms

Nonhormonal treatment can be appropriate when HRT is medically unsuitable, not preferred or insufficient for a particular problem. The options depend on the symptom. A treatment for hot flushes is not automatically a treatment for vaginal pain, insomnia or depression, and “nonhormonal” does not mean risk-free. [1]

A useful consultation begins by identifying the main target, reviewing other medicines and discussing the evidence, adverse effects, monitoring and local availability of each option. You do not have to choose between receiving no help and accepting hormones. Equally, a nonhormonal label should not excuse exaggerated claims or inadequate assessment.

Match the treatment to the symptom

For vasomotor symptoms, meaning hot flushes and night sweats, options can include selected prescription medicines and menopause-specific psychological approaches. Persistent insomnia may need CBT for insomnia or another sleep-focused intervention. Vaginal dryness may respond to local moisturisers, lubricants or other targeted treatment. [1] [2] [3]

Depression and anxiety require assessment in their own right. A medicine prescribed for a mood disorder and the same medicine used for hot flushes may involve different goals and dosing. The familiar name of a drug does not tell you why it is being offered.

Ask the clinician to explain which symptom each part of the plan addresses. This avoids unrealistic expectations and makes review more useful. It also reduces the temptation to keep adding products when the original problem has not been clearly defined.

Selected antidepressant medicines

Some medicines in the SSRI and SNRI groups can reduce vasomotor symptoms in selected patients. They may be considered even when the person does not have depression. Product approval, prescribing practice and the strength of evidence vary by medicine and country. [1]

Potential adverse effects and interactions matter. A clinician should review other medicines, previous experiences, mood history and any relevant cancer treatment. If a drug is also intended to treat depression or anxiety, that purpose and the expected follow-up should be explicit.

Do not start, combine or stop these medicines independently. Some need a planned reduction when stopping, and a treatment that was unsuitable once may have been unsuitable for reasons specific to that situation. Ask how long an adequate trial should last and what would count as a reason to change course.

Gabapentin and other established options

Gabapentin may be used for hot flushes in some settings, although it is more familiar as a medicine for other conditions. Sedation or dizziness can be relevant, especially when driving, working at height or using other medicines that affect alertness. Prescribing should account for the full medical history. [1]

Other medicines are sometimes considered, but they do not all have equivalent evidence or tolerability. A long list of available drugs is less helpful than an explanation of why one is being proposed for your circumstances.

Ask about licensing status for the specific use. Off-label prescribing can be appropriate when supported by clinical judgement and evidence, but the prescriber should explain it. It is not the same as a product being proven ineffective, and it is not permission to omit informed consent, monitoring or a clear review plan.

Neurokinin-targeting medicines

Newer nonhormonal medicines target pathways involved in temperature regulation. Fezolinetant is a neurokinin-3 receptor antagonist used for moderate to severe menopause-related vasomotor symptoms. It is not intended to replace all the other roles or effects of hormone therapy. [4]

In the United States, elinzanetant, marketed as Lynkuet, has also been approved for moderate to severe vasomotor symptoms. It targets neurokinin receptors through a different profile. Approved status does not establish that it is the best option for every person or available under every insurance plan. [5]

Ask about the exact product, local approval, interactions, contraindications and monitoring. Different medicines should not be treated as interchangeable simply because both are described as new nonhormonal menopause tablets. A clinician should use the current prescribing information for the country and formulation being supplied.

Liver safety with fezolinetant

Fezolinetant has an important risk of rare but serious liver injury. FDA advice calls for liver blood tests before treatment, monthly during the first three months, and at months six and nine. Local instructions may differ, so the prescriber must explain the schedule that applies to your medicine. [4]

Symptoms such as yellowing of the eyes or skin, dark urine, unusual itching, abdominal pain or marked new tiredness can require immediate action. Regulators advise stopping fezolinetant and contacting the prescriber promptly if symptoms suggest liver injury. Do not wait for the next routine blood test. [6]

This monitoring is part of treatment, not an optional extra. Before starting, clarify who orders the tests, who reviews results, what they cost and how urgent advice is obtained. A service that supplies the medicine without a workable monitoring pathway has not provided a complete care plan.

Menopause-specific CBT and CBT for insomnia

Menopause-specific cognitive behavioural therapy can help with the impact of hot flushes, sleep difficulties and associated distress. It may be considered alongside HRT or when hormones are not suitable or preferred. This approach does not imply that the physical symptoms are imaginary. [7]

CBT for insomnia is a more specifically sleep-focused intervention. It addresses patterns that maintain persistent sleep difficulty, not merely the temperature event that first caused waking. Some people may benefit from combining symptom treatment with this separate sleep work. [2]

Ask about the actual intervention, the practitioner’s training, session format and outcome measures. General relaxation advice is not automatically equivalent to a structured evidence-based programme. Choose goals that matter to you, such as less avoidance of meetings or returning to sleep more easily, rather than a promise that therapy will stop every flush.

Nonhormonal options for vaginal comfort

Lubricants can reduce friction during sexual activity, while vaginal moisturisers are used regularly for dryness. Product choice should consider irritation, comfort and the intended use. Persistent pain, bleeding, discharge or urinary symptoms need assessment rather than repeated self-treatment. [3]

Pelvic-health or psychosexual support may be relevant when muscle function, pain-related fear or relationship circumstances contribute. These approaches should follow assessment and should not place pressure on someone to resume an activity they do not want.

Low-dose vaginal oestrogen is hormonal, but its local exposure and risk discussion differ from systemic HRT. Some people who avoid systemic hormones may still be able to discuss local treatment, including a carefully individualised conversation after cancer. Do not assume the same rule applies to every hormone product. [8]

Lifestyle measures: useful support, not guaranteed treatment

A comfortable sleeping environment, suitable clothing, regular activity and noticing personal triggers can help make symptoms more manageable. These steps support health and comfort, but persistent symptoms are not proof that someone has failed to exercise or eat correctly. [9]

Avoid programmes that turn symptom management into a rigid list of forbidden foods or expensive daily rituals. Choose changes that are feasible and evaluate whether they help the problem you are trying to address.

Alcohol may worsen sleep or complicate medication use, and smoking cessation can support longer-term health. A clinician can help when changing substance use is difficult. Dependence or withdrawal concerns require a supported plan; a wellness retreat should not present an unsupervised detox as routine menopause care.

Supplements and unproven alternatives

Herbal and complementary products vary in evidence, manufacturing consistency and safety. A product may interact with prescription medicines or be unsuitable with certain conditions. Natural origin is not a reliable measure of benefit or risk. [10]

Ask whether the specific preparation has been studied, what outcome was measured, and whether the result is relevant to your symptoms. An ingredient’s theoretical mechanism or a testimonial does not establish that the product works in practice.

Be particularly cautious about claims to cure menopause, restore youthful hormone levels or replace cancer-related medical advice. Discuss any supplement with a pharmacist or clinician and include it on the medication list. Avoid paying for a large package before the service has explained what is evidence-based, what is uncertain and what is simply optional wellbeing support.

Keep the reason for each treatment visible when several are combined. A medicine intended to reduce hot flushes may not address a separate sleep disorder, while therapy for insomnia has a different target from moisturising treatment for vaginal discomfort. Reviewing each target separately makes it easier to recognise partial benefit and avoid abandoning a useful approach because it did not solve an unrelated symptom. Ask the clinician to prioritise changes so that response and adverse effects can be interpreted clearly.

A workable nonhormonal care plan

The plan should state the symptom target, treatment choice, important adverse effects, interaction checks, monitoring and review. It should also explain what happens if the first option is ineffective or unacceptable. A preference to avoid hormones should lead to a thoughtful discussion, not an assumption that any alternative will do.

Availability and payment differ across countries and services. Check the current local pathway rather than relying on an old approval announcement or a price quoted elsewhere. Prescription access without follow-up is not the same as coordinated care.

Use the appointment planner to record priorities and concerns. Nonhormonal care works best when it is specific, evidence-informed and proportionate, with realistic expectations about what each treatment can and cannot achieve.